drugset / Trial / NCT03141671

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

NCT03141671

RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).

Timeline

Start
2017-11-24
Primary completion
2025-04-05
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule Oral
Subject Apalutamide Small molecule Oral
Subject Bicalutamide Other / unclassified Oral
Background Prednisone Other / unclassified Oral

Indications